Evidence map›Paper›PMID 38665530›Full record

ArticleChemical science2024

An efficient mRNA display protocol yields potent bicyclic peptide inhibitors for FGFR3c: outperforming linear and monocyclic formats in affinity and stability.

Camille Villequey, Silvana S Zurmühl, Christian N Cramer, Bhaskar Bhusan, Birgitte Andersen, Qianshen Ren, Haimo Liu, Xinping Qu, Yang Yang, Jia Pan and 2 more

Abstract read
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. De novo discovery of bicyclic cysteine-rich peptides targeting gasdermin D.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Camille VillequeyGlobal Research Technologies, Novo Nordisk A/S Novo Nordisk Park 2760 Måløv Denmark cmvq@novonordisk.com.ORCID https://orcid.org/0009-0005-2247-0382
Silvana S ZurmühlGlobal Research Technologies, Novo Nordisk A/S Novo Nordisk Park 2760 Måløv Denmark cmvq@novonordisk.com.
Christian N CramerGlobal Research Technologies, Novo Nordisk A/S Novo Nordisk Park 2760 Måløv Denmark cmvq@novonordisk.com.ORCID https://orcid.org/0000-0001-9455-4212
Bhaskar BhusanDepartment of Chemistry, Oxford University, Chemistry Research Laboratory 12 Mansfield Road Oxford UK.
Birgitte AndersenGlobal Drug Discovery, Novo Nordisk A/S Novo Nordisk Park 2760 Måløv Denmark.
Qianshen RenNovo Nordisk Research Center China, Novo Nordisk A/S Shengmingyuan West Ring Rd, Changping District Beijing China.
Haimo LiuNovo Nordisk Research Center China, Novo Nordisk A/S Shengmingyuan West Ring Rd, Changping District Beijing China.
Xinping QuNovo Nordisk Research Center China, Novo Nordisk A/S Shengmingyuan West Ring Rd, Changping District Beijing China.
Yang YangNovo Nordisk Research Center China, Novo Nordisk A/S Shengmingyuan West Ring Rd, Changping District Beijing China.
Jia PanNovo Nordisk Research Center China, Novo Nordisk A/S Shengmingyuan West Ring Rd, Changping District Beijing China.
Qiujia ChenNovo Nordisk Research Center China, Novo Nordisk A/S Shengmingyuan West Ring Rd, Changping District Beijing China.
Martin MünzelGlobal Research Technologies, Novo Nordisk A/S Novo Nordisk Park 2760 Måløv Denmark cmvq@novonordisk.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrocyclization has positioned itself as a powerful method for engineering potent peptide drug candidates. Introducing one or multiple cyclizations is a common strategy to improve properties such as affinity, bioavailability and proteolytic stability. Consequently, methodologies to create large libraries of polycyclic peptides by phage or mRNA display have emerged, allowing the rapid identification of binders to virtually any target. Yet, within those libraries, the performance of linear

Identifiers

PMID38665530
PMCPMC11040643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.